Sens. Dick Durbin (D-IL) and Roger Marshall (R-KS) are calling on the FDA to take action against a Super Bowl ad coming on ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

The Trump administration's reported plans to potentially lay off thousands of FDA employees could slow the agency’s reviews ...

Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for ...

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about ...

The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, ...

China blacklists Illumina amid tensions with the US, threatening its market access, while US actions limit Chinese rival MGI; CEO Jacob Thaysen seeks resolution as stock falls.

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...